Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | PER2 | O15055 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892974 | 0.78 | L3MBTL1 (0.53) | CCNA2CDK2CCNA1HRH3ABL1 | |
| SCHEMBL13626389 | 0.78 | CCNA2 (0.45) | CCNA2CDK2CCNA1PTGER2PTGER4 | |
| SCHEMBL9893010 | 0.77 | CCNA2 (0.46) | CCNA2CDK2CCNA1HRH3PER2 | |
| SCHEMBL22352609 | 0.76 | PTGER2 (0.59) | CCNA2CDK2CCNA1PTGER2PTGER4 | |
| SCHEMBL13626386 | 0.76 | PTGER2 (0.59) | CCNA2CDK2CCNA1PTGER2PTGER4 | |
| SCHEMBL6788699 | 0.75 | CCNA2 (0.55) | CCNA2CDK2CCNA1PTGER2LMNA | |
| SCHEMBL11112763 | 0.75 | ESR1 (0.49) | CCNA2CDK2CCNA1HRH3PER2 | |
| SCHEMBL13695442 | 0.73 | DHODH (0.47) | DHODHHRH3LMNA | |
| SCHEMBL4636834 | 0.73 | GAA (0.46) | CCNA2CDK2CCNA1ABL1LMNA | |
| SCHEMBL13626382 | 0.72 | PTGER2 (0.42) | CCNA2CDK2CCNA1PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | DHODH 1858/4885CCNA2 1927/4885CDK2 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.